Showing 211-220 of 1560 results for "".
Targeted Therapies in Cancer Research
https://reachmd.com/programs/clinicians-roundtable/targeted-therapies-in-cancer-research/1596/Dr. Steve Kron, Associate Professor, Molecular Genetics and Cell Biology at the University of Chicago, and a member of the Committees on Genetics, Cancer Biology, Cell Physiology, and Molecular Medicine discusses targeted therapies in cancer research.Life as a Physician Scientist
https://reachmd.com/programs/clinicians-roundtable/life-as-a-physician-scientist/1598/Dr. Steve Kron, Associate Professor, Molecular Genetics and Cell Biology at the University of Chicago, and a member of the Committees on Genetics, Cancer Biology, Cell Physiology, and Molecular Medicine discusses the life of a physician scientist.Novel Treatments for Diabetes
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/novel-treatments-for-diabetes/1787/Dr. Lazar discusses exciting new innovations in our approach to both type I and type II diabetes including Islet cell transplantation, medications for beta cell preservation and new insights into the control of obesity.Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
https://reachmd.com/clinical-practice/oncology-hematology/amivantamab-monotherapy-or-in-combination-with-paclitaxel-in-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-origami-4-study-results/39780/In the phase 1b/2 OrigAMI-4 trial, amivantamab alone or with paclitaxel showed strong and durable responses in previously treated recurrent or metastatic HNSCC.Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
https://reachmd.com/clinical-practice/oncology-hematology/cohort-9-of-the-phase-2-ev-202-trial-first-line-enfortumab-vedotin-plus-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma/39779/In cohort 9 of EV-202, first-line enfortumab vedotin plus pembrolizumab showed promising and durable responses in patients with recurrent or metastatic HNSCC.Managing Capillary Leak Syndrome: Early Recognition and Intervention in BPDCN Care
https://reachmd.com/programs/medical-industry-feature/managing-capillary-leak-syndrome-early-recognition-and-intervention-in-bpdcn-care/29929/Capillary leak syndrome is a significant adverse event of blastic plasmacytoid dendritic cell neoplasm therapy. Here’s how to recognize and treat it.Unraveling the Mechanism: How Ocrelizumab Impacts Cortical Lesions in MS
https://reachmd.com/programs/neurofrontiers/unraveling-the-mechanism-how-ocrelizumab-impacts-cortical-lesions-in-ms/32367/While B-cell follicles in the brain’s meninges were previously suspected to drive cortical lesions in multiple sclerosis (MS), studies show ocrelizumab has little impact on B-cell follicles—yet it still significantly reduces cortical lesions. This suggests that another, yet-to-be-understood B-cell-mEnlisting Students in the Fight Against COVID-19: Helpful or Harmful?
https://reachmd.com/programs/covid-19-frontlines/enlisting-students-fight-against-covid-19-helpful-or-harmful/11325/Medical students are increasingly being thrust into frontline efforts to combat COVID-19. Will this help stem the tide, or compound the crisis?The Henrietta Lacks Foundation Gives Back
https://reachmd.com/programs/clinicians-roundtable/the-henrietta-lacks-foundation-gives-back/6325/In 1951, cancer killed an impoverished young African American mother named Henrietta Lacks. Cells biopsied from her tumor, without her or her family's knowledge, went on to be critical in establishing an important cell line, known as HeLa, that has been part of a medical revolution. HeLa cells haveExosome Therapy for Pelvic Tissue Regeneration
https://modernaesthetics.com/ma-issues-index/september-october-2025/exosome-therapy-for-pelvic-tissue-regeneration/39268/Preclinical studies highlight potential applications for vaginal mesh complications, anal sphincter injury, and urinary incontinence